**76th SCIENTIFIC SESSIONS CORPORATE SYMPOSIA AT-A-GLANCE**

**FRIDAY, JUNE 10, 2016:**

**11:30 a.m. – 1:45 p.m.**
A Case-Based Approach to Understanding a Once Daily Basal Insulin Option for Your Patients  
*Sponsored by Novo Nordisk*

(11:30 a.m. – 11:50 a.m. – Registration / 11:50 a.m. – 1:30 p.m. – Symposium)

Join our expert faculty for a review of a once-daily basal insulin. Using case studies, the faculty will discuss topics ranging from clinical pharmacology, review of clinical data, and practical considerations with regard to dosing and titration.

**Location:** Hilton New Orleans Riverside, Grand Ballroom A-B  
**Contact:** Ken Paprockas / Phone: 312-621-7172

**6:30 p.m. – 9:30 p.m.**
¿Hacia dónde vamos con el tratamiento de diabetes? (Presentado en Español)  
*Patrocinado de manera conjunta por el University of Texas Southwestern Medical Center y Worldwide Initiative for Diabetes Education*  
*Apoyado por una beca educational no restringida de Novo Nordisk A/S*

(6:30 p.m. – 7:00 p.m. – Registration and Dinner / 7:00 p.m. – 9:30 p.m. – Educational Program)

La diabetes tipo 2 es una enfermedad progresiva que a menudo conduce a la necesidad del tratamiento con insulina. Nuestro simposio explorará los beneficios clínicos de las nuevas y prometedoras tendencias en la atención de la diabetes, con el fin de alcanzar el control glucémico personalizado, lo que comprende: la necesidad de las insulinas de rápida acción, cómo los agonistas del receptor de GLP-1 mejoran el tratamiento y qué combinaciones terapéuticas son mejores.

**Location:** Hilton New Orleans Riverside, Grand Ballroom A-B  
**Contacts:**  
Mark Vinciguerra, University of Texas Southwestern Medical Center / Phone: 214-648-4852 / E-mail: Mark.Vinciguerra@UTSouthwestern.edu  
Jane Savio, Worldwide Initiative for Diabetes Education / Phone: 212-614-4337 / E-mail: Jane.Savio@worldwidediabetes.org

**6:30 p.m. - 9:30 p.m.**
Therapeutic Advances and Practical Strategies for Complementary Basal Insulin Plus Incretin System-Targeted Agents in Complex Patients with Diabetes  
*Sponsored by CMEducation Resources*  
*Supported by an educational grant from Sanofi Diabetes*

A nationally known faculty of diabetes management experts discusses the role, indications, guidelines, and evidence supporting optimal approaches to early use and intensification of basal insulin therapy for
FPG dysregulation in diabetes; and subsequently, the use of basal insulin in combination with GLP-1 receptor agonists to optimize glycemic (FPG and PPG) control so that diabetes and endocrinology specialists can achieve desired ADA HbA1c target goals.

**Location:** Hilton New Orleans Riverside, Grand Ballroom C-D  
**Contact:** Milo Falcon / Phone: 678-662-1132

**6:30 p.m. - 9:30 p.m.**  
**Optimizing Management of the Diabetic Heart**  
**Sponsored by** CMEducation Resources  
**Supported by an educational grant from** Sanofi and Regeneron Pharmaceuticals

World authorities on CV risk reduction in diabetes, hypercholesterolemia, LDL-focused management of hyperlipidemia, atherosclerosis and CV medicine address landmark clinical trials, mechanisms of atherosclerotic heart disease, novel LDL targets and therapies, new translational dimensions of applying advances in LDL reduction to the diabetic population.

**Location:** Sheraton New Orleans, Grand Ballroom D-E  
**Contact:** Milo Falcon / Phone: 678-662-1132

**SATURDAY, JUNE 11, 2016:**

**5:30 a.m.- 7:45 a.m.**  
**Clinical Issues in Type 2 Diabetes: Consensus and Controversies Around Intensifying Noninsulin Therapy**  
**Jointly provided by** Global Education Group and Integritas Communications  
**Supported by an educational grant from** AstraZeneca

(5:30 a.m. – 5:45 a.m. – Breakfast/Registration / 5:45 a.m. – 7:45 a.m. – Symposium)

During this Clinical Issues™ program, a panel of experts in diabetes research and patient care will discuss and debate a series of educational topics related to the efficacy, safety, and practical use of noninsulin combination therapy for various patient types with type 2 diabetes.

**Location:** Hilton New Orleans Riverside, Grand Ballroom C-D  
**Contact:** Matt Wong / Phone: 646-350-0902

**5:30 a.m.- 7:45 a.m.**  
**The Next Step in Continuous Glucose Monitoring-Making Diabetes Management Decisions with Sensor Glucose Information**  
**Sponsored by** cgmEDUCATION.net  
**Supported by an educational grant from** DEXCOM

Significant improvements in accuracy of Continuous Glucose Monitoring (CGM) sensors and device algorithms have made CGM-based treatment decisions a near-term possibility. This program will
evaluate the potential clinical application and use of CGM in diabetes management decisions and the importance of various aspects of CGM to guide optimal treatment.

**Location:** Sheraton New Orleans, Grand Ballroom A-C  
**Contact:** Jeffrey Rosenberg / E-mail: info@cgmeducation.net

**6:15 p.m. - 9:00 p.m.**  
**CV Outcomes with Antihyperglycemic Therapy: Past, Present, and Future Impact on Practice**  
*Supported by Medscape Education*  
*Supported by an educational grant from Boehringer Ingelheim Pharmaceuticals Inc. and Lilly USA, LLC*

(6:15 p.m. – 6:45 p.m. – Dinner and Registration / 6:45 p.m. – 9:00 p.m. – Presentation)

Findings from studies of glucose-lowering agents—DPP-4 inhibitors, GLP-1 RAs and SGLT2 inhibitors — have emerged recently. Combined with CV outcomes from studies of the conventional oral T2D drugs—metformin, TZDs, and sulfonylureas—there is increasing evidence to aid physicians in individualizing treatment plans in patients with CVD/elevated CV risk.

**Location:** Sheraton New Orleans, Grand Ballroom A-C  
**Contact:** Jeruza Alves / Phone: 212-417-9682

**6:15 p.m. - 9:15 p.m.**  
**The Physiologic Basis for Optimizing Glycemic Control with BASAL INSULIN in COMPLEX PATIENTS with DIABETES**  
*Supported by CMEducation Resources*  
*Supported by an educational grant from Sanofi Diabetes*

A panel of experts analyzes the use of long-acting insulin-based therapies in diabetes management; and how, by determining the optimal risk-benefit profile for such agents, clinicians may better able meet HbA1c target goals. They will review insulin formulations under development or recently introduced that may provide improved efficacy and safety.

**Location:** Hilton New Orleans Riverside, Grand Ballroom A-B  
**Contact:** Milo Falcon / Phone: 678-662-1132

**6:15 p.m. - 9:15 p.m.**  
**Friedman Fellows Symposium**  
*Supported by Gerald J. Friedman Fellows Program*  
*Supported by an educational grant from The Gerald J. and Dorothy R. Friedman New York Foundation for Medical Research*

Friedman Fellows will present their posters to Dr. Jesse Roth and attendees followed by dinner and Dr. Roth’s presentation. Title of the presentation: “Unveiling the new (brighter) face of metabolic syndrome.”

Updated 5/10/16
**Location:** Sheraton New Orleans, Grand Ballroom D-E  
**Contact:** BG Hacker / Phone: 917-771-0470

**SUNDAY, JUNE 12, 2016:**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
</table>
| 6:45 p.m. - 9:30 p.m. | **Options and Outcomes: Individualizing Therapy to Help Your Patients with T2DM Achieve Their Weight-Loss Goals**  
*Provided by Institute of Medical and Nursing Education (IMNE)*  
*Supported by an educational grant from Novo Nordisk*  
Clinicians who treat adult patients with T2DM should also be prepared to provide individualized, patient-centered obesity management. Participants will have the opportunity to review and apply obesity treatment recommendations based on video vignettes that portray patient experiences and perspectives, with commentary and advice from expert faculty. |

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
</table>
| 6:45 p.m. - 9:45 p.m. | **Two Years of Flash Glucose Monitoring: The Global Clinical Experience**  
*Sponsored by Abbott Diabetes Care*  
*Supported by an educational grant from Abbott Diabetes Care*  
*(6:45 p.m. – 7:45 p.m. – Light Supper / 7:45 p.m. – 9:45 p.m. – Program)*  
The program will consist of a discussion of recent trial data obtained with FreeStyle Libre Pro in people with type 2 diabetes in the US; the clinical experience with FreeStyle Libre Pro in India; and the use of real time sensor data in people with type 1 diabetes using FreeStyle Libre in Europe. |

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
</table>
| 6:45 p.m. - 9:45 p.m. | **Partnering to Improve Patient Care: A Technological Evolution in Insulin Delivery**  
*Sponsored by Johnson & Johnson Diabetes Care Companies*  
Please join us to hear expert faculty discuss the evolution of insulin delivery systems for patients with type 1 diabetes. Symposium attendees will have the opportunity to gain insight on technological advancements in insulin delivery, including the shift from reactive to predictive delivery systems. |

**Location:** Hilton New Orleans Riverside, Grand Ballroom A-C  
**Contact:** Cindy Molnar / Phone: 404-443-1517 / E-mail: cindy.molnar@imne.com

**Location:** Hilton New Orleans Riverside, Napoleon Ballroom  
**Contact:** Alex Ananou / Phone: 604-601-8610
7:00 p.m. - 9:45 p.m.
Concentrated Insulin: Deciphering the When and the How for Better Patient Outcomes
Sponsored by Medscape
Supported by an educational grant from Eli Lilly and Company

(7:00 p.m. – 7:30 p.m. – Registration / 7:30p.m. – 9:45 p.m. – Presentation)

Providing an appropriate amount of insulin measured in 100 units/mL (U-100) can be difficult in patients with high insulin dose requirements. This mix of foundation, cases and panelists discussion will examine clinical and practical aspects of concentrated insulin use, including dosing options/delivery devices, patient selection, and strategies for individualizing therapy.

Location: Sheraton New Orleans, Grand Ballroom D-E
Contact: Jeruza Alves / Phone: 212-417-9682

MONDAY, JUNE 13, 2016:

6:45 p.m. – 9:45 p.m.
Confronting Barriers to Glycemic Control with New and Emerging Insulin and Combination Therapies
Jointly sponsored by Johns Hopkins University School of Medicine and Medical Logix, LLC
Supported by an educational grant from Novo Nordisk

Delays in initiation/intensification of basal insulin contribute to inadequate glycemic control rates among T2DM patients. Injectable therapy use may be deferred because of delivery mode and lack of familiarity with new and emerging medication advantages/limitations. This iCase Challenge symposium provides a dynamic and interactive format designed to support practice improvement.

Location: Hilton New Orleans Riverside, Grand Ballroom A-B
Contact: Michael Speidel / Phone: 215-219-5793

6:45 p.m. – 9:45 p.m.
SGLT2 Inhibitors for T2D: Effect on Glucose Homeostasis and Nonglycemic Outcomes
Sponsored by Medscape Education
Supported by an educational grant from AstraZeneca

This CME/CE live satellite symposium that will provide a summary of safety data for SGLT2 Inhibitors related to effects on glycemic and nonglycemic parameters, specifically weight and the cardiovascular and renal systems, as well as, explore the clinical definition of quality glucose control and what it means for individualized treatment plans.

Location: Grand Ballroom A-C, Sheraton New Orleans
Contact: Colleen Healy / Phone: 860-205-7534